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biomarkers from biospecimens archived from patients en-
rolled in randomized clinical trials offer the greatest oppor-
tunity to develop and validate high-value molecular diag-
nostics. An alternative opportunity is to access high-quality 
biospecimens collected from large public and private longi-
tudinal observational cohorts such as the UK Biobank, the US 
Million Veteran Program, the UK 100,000 Genomes Project, 
or the French E3N cohort. Value-based diagnostics can be 
developed to work in a range of samples including blood, 
serum, plasma, urine, and tumour tissue, and better access 
to these high-quality biospecimens with clinical data can
facilitate biomarker research.  © 2016 S. Karger AG, Basel 
 Introduction 
 Although biomarker studies continue to accumulate 
in the published literature, few of these biomarkers are 
being adopted into routine clinical practice, for several 
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 Abstract 
 The challenges faced in developing value-based diagnostics 
has resulted in few of these tests reaching the clinic, leaving 
many treatment modalities without matching diagnostics
to select patients for particular therapies. Many patients re-
ceive therapies from which they are unlikely to benefit, re-
sulting in worse outcomes and wasted health care resources. 
The paucity of value-based diagnostics is a result of the sci-
entific challenges in developing predictive markers, specifi-
cally: (1) complex biology, (2) a limited research infrastruc-
ture supporting diagnostic development, and (3) the lack of 
incentives for diagnostic developers to invest the necessary 
resources. Better access to biospecimens can address some 
of these challenges. Methodologies developed to evaluate 
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reasons including the following: (1) insufficient evidence 
supports their use, (2) the patient population where they 
are applicable is too small, and (3) there are false discov-
eries that do not hold up in subsequent testing due to ir-
reproducible assays or a sampling bias  [1, 2] . One of the 
more efficient approaches to avoiding these problems is 
to conduct studies using biospecimens from previously 
conducted clinical trials archived under standardized 
conditions in biobanks. Biomarker studies based on sam-
ples from biobanked tissue have been shown to be less 
expensive to conduct and to provide results sooner than 
from relying on prospectively collected biosamples  [3] . 
Developing clinically robust biomarkers requires access 
to the right biospecimens. While this approach offers 
great promise, identifying high-confidence biomarkers 
generally requires sufficient samples from at least two in-
dependent clinical trial cohorts with similar study designs 
to be considered level-one evidence of clinical utility  [4] . 
The European Medicines Agency demonstrated one of 
the first applications of this approach when it approved 
the use of cetuximab and panitumumab in metastatic 
colorectal cancer patients with wild-type KRAS tumours. 
KRAS testing was validated as a companion diagnostic 
based on biobanked tissue from four randomized clinical 
trials  [5] . Additionally, multiple prospective studies using 
archived tissue from observational registries can be con-
sidered level-two evidence  [4, 6–10] . These examples 
demonstrate how biobanked tissue can greatly facilitate 
the development and validation of clinically useful bio-
markers – and, conversely, how different biospecimen 
cohorts offer value depending on the clinical setting in 
which they were collected. As new, more comprehensive 
analysis technologies such as next-generation sequencing 
or mass spectrometry protein profiling increase the 
breadth and depth of interrogation into biological pro-
cesses, the demand for biological samples to conduct ap-
propriately sized studies will continue to grow.
 One case study for successfully validating a molecular 
diagnostic test using archived samples is the Oncotype ® 
DX Breast Cancer Assay. A recent study published in the 
 New England Journal of Medicine described the first re-
sults from the TAILORx study, in which patients were 
prospectively assigned to chemotherapy or hormonal 
therapy alone based on the Oncotype DX score. This 
analysis showed that 99.3% of the patients with Oncotype 
DX assay recurrence scores between 0 and 10, treated 
with endocrine therapy alone, remained free of distant 
recurrence at 5 years  [11] . This result replicates the results 
of the original NSABP B-14 validation study that was 
based on analysing archived fixed tissue samples, where a 
similar group of patients with the same treatment regi-
men had a rate of distant recurrence-free survival at 5 
years of 98.6%  [12, 13] .
 Optimal Process for Collecting Biospecimens from 
Studies 
 The most important criteria for any study biospeci-
mens are that (1) biosamples are collected and stored fol-
lowing high quality standards and consistent protocols 
that consider the downstream assays and analyses, (2) 
sufficient clinical data are known to help characterize 
each patient’s disease, (3) metadata describing sample 
collection, pre-analytical processing, quality control as-
sessment, and the storage method are available, and (4) 
patients have provided broad informed consent for their 
tissue to be used for exploratory research beyond the 
scope of the clinical trial. Since each effort in biomarker 
development may require specific biospecimen cohorts, 
providing researchers with the capability to search for ap-
propriate specimen resources available in biobanks can 
facilitate the successful development of high-value diag-
nostics helping to advance personalized or precision 
medicine  [14, 15] .
 Considering the high research value of samples from 
randomized clinical studies, special attention should be 
focused on collecting these samples according to stan-
dardized procedures and storing them under controlled 
conditions. The first priority should be securing one-time 
informed consent from each patient for future biomarker 
research according to the requirements of each specific 
jurisdiction. In a high proportion of cases, patients are 
willing to provide their consent to contributing their bio-
logical material and medical data to a biobank as long as 
they understand the general scope of the research and are 
properly informed of the risks and benefits of the re-
search. Often patients are not aware of the purpose and 
existence of biobanks prior to being enrolled in a clinical 
study. One observational study of 430 cancer patients in 
Italy found that only 64.5% of the patients were aware of 
biobanks prior to the study, and the rate was lower among 
less-educated patients  [16] . Therefore, high consent rates 
are more likely if patients are educated by a health care 
professional about the benefits their biospecimen dona-
tion may bring to medical research. Even clinical studies 
that involve healthy patients, such as vaccination or 
screening trials, should prioritize collecting genetic mate-
rial for biobanking and can achieve a high rate of consent 
for collecting genetic material for biobanking  [17] . It is 
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key that an appropriate and systematic approach for con-
senting patients be established to support the collection 
of biological material, especially in multicentre clinical 
trials. For biomarker studies from archived biospeci-
mens, it is generally recommended that at least two thirds 
of the samples be available from the parent study to pow-
er the statistical analysis of predictive biomarkers; thus, 
focusing efforts on obtaining consent from a large frac-
tion of enrolled patients for sample collection and analy-
sis is an important first step  [11] .
 Secondly, establishing appropriate protocols for col-
lecting and storing biological material should be estab-
lished as part of the study design. Often, financial limita-
tions constrain decisions on which specimens are collect-
ed, so investigators should be thoughtful regarding what 
may be feasible and which samples may provide the high-
est analytical value for gaining insight into the therapeu-
tic regimen being tested. For example, collecting baseline 
biospecimens from patients prior to treatment, at various 
time points throughout the course of treatment, and at 
disease progression or recurrence provides a longitudinal 
view of response to the therapy being tested. In the case 
of metastatic oncologic disease, specimens collected from 
different anatomical sites may provide insight into dis-
ease heterogeneity and resistance to therapy and support 
the discovery of molecular resistance mechanisms. In ad-
dition, a future research benefit may be realized from ar-
chived biospecimens carefully collected with control or 
reference tissue. The biospecimen collection should be 
included as part of the clinical trial design to ensure that 
all specimens are collected and quality is controlled and 
preserved using optimized standard protocols to reduce 
the impact of pre-analytical factors. Studies have shown 
that a high degree of concordance between frozen and 
formalin-fixed paraffin-embedded (FFPE) tissue may be 
attained for gene expression analyses on common plat-
forms such as oligonucleotide microarrays, next-genera-
tion sequencing, PCR product resolution melting analy-
sis for genotyping or copy numbers, real-time RT-PCR, 
digital PCR, nCounter technology, and DASL bead arrays 
 [18] . While these analytical methods may have been dem-
onstrated to be concordant in the limited number of pub-
lished studies, these findings often collapse when general-
ized into high-throughput contract laboratory settings 
where scale-up factors and specimen variability may im-
pact assay accuracy and lead to false conclusions  [14] . 
Each biomarker assay needs to be validated for the effects 
of pre-analytical procedures and variability of biosample 
properties to ensure the reliability of assay results. Ideally, 
investigators would bank clinical study biomaterials at a 
central, certified biobank with established, stringent qual-
ity control and quality assurance measures. One such 
measure would be to have a reference panel of biomarkers 
markers used to monitor the molecular integrity of the 
biospecimens across their life span  [19] . Furthermore, all 
biospecimens should be linked to the appropriate docu-
mentation of relevant quality parameters as well as clini-
cal data in a way that supports research while protecting 
patient health information.
 As biospecimens from clinical trials (especially pro-
spective randomized trials) are extremely precious for fu-
ture research, proper governance and decision-making 
should be implemented to ensure that these samples are 
used for research projects with a high potential for mean-
ingful discovery. Ideally, an independent process should 
be established to afford a diverse group of investigators 
the opportunity to request access to banked biospeci-
mens. Improving access to quality-defined biospecimens 
is a major goal of the European Biobanking and Bio-
molecular Resources Research Infrastructure (BBMRI-
ERIC). Therefore, biobanks should be open for external 
research proposal requests, and the evaluation procedure 
of such requests should be publicly available as a trans-
parent regulatory document that includes a method for 
contacting a resource who deals with research requests. 
Furthermore, the evaluation process should include in-
ternal biobank scientists to stimulate cooperation among 
investigators and maximize the research usability of the 
biospecimens  [20] . Patient organizations or other key 
stakeholders should be involved in the decision-making 
process. For example, the Southwestern Oncology Group 
(SWOG) in the USA invites a broad range of research in-
vestigators to submit proposals for consideration, and it 
evaluates study concepts through a Triage Committee 
composed of internal and external advisors according to 
the following criteria  [21] : (1) significance of proposed 
research; (2) expertise of investigator(s); (3) innovation; 
(4) technical approach, and (5) research environment. 
Patient organizations for rare diseases, including rare 
cancers, have proven to be a powerful resource in orga-
nizing their member patients to gain a needed critical 
mass of biospecimen samples to support biomarker re-
search.
 Cooperative study groups should be encouraged to 
support a broad range of research projects while prioritiz-
ing the most promising approaches, since the amount of 
biospecimens from prospective clinical trials is often 
quite limited. Biomarker investigators should be required 
to optimize their use of samples to maximize opportuni-
ties for further research based on these samples. Similarly, 
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it should be required that research studies supported by 
biobank specimens provide open access to the research 
results generated by the use of human biospecimens  [22] , 
although this principle may be limited by the requirement 
to protect the privacy of sample donors and any restric-
tions specified in the informed consent forms.
 Banking biosamples from population-based cohorts 
or from patients treated in hospitals holds significant re-
search potential but is infrequently done today. Some 
countries and regions have centrally organized disease 
registries with links to biospecimens in biobanks, and 
these samples may be used to address research questions 
not feasible to ask from clinical trial samples. For exam-
ple, elderly patients or women of childbearing age are of-
ten excluded from randomized clinical trials, which may 
cause a major selection bias. Biospecimens from these 
sources may complement those from clinical trials so that 
important clinical questions may be asked of a more rep-
resentative population. The value of these samples can be 
optimized if the samples and data are collected in a stan-
dardized manner. Often, biomarker discovery studies re-
quire the biospecimen source to be a homogenous group 
of patients receiving the same treatments.
 One of the best examples of a population-based regis-
try is in Denmark, where a large, comprehensive biobank 
provides investigators with a valuable research resource. 
In 1997, the Danish National Pathology Registry (DNPR) 
initiated a process to allow biospecimens to be used for 
clinical research, supplying the whole country with a 
comprehensive resource including a limited number of 
pathology services and consistent, careful sample han-
dling that reduces the number of sources of bias. All Dan-
ish citizens have a unique personal identifier, which can 
facilitate linking different databases and allows innova-
tive data mining for research studies. Similar to the pro-
cess mentioned for the SWOG, the Danish National 
Board of Health has an application process which permits 
investigators to request use of the data. To access biolog-
ical specimens, approval is required from the Danish Na-
tional Committee on Biomedical Research Ethics as well 
as the local pathology department holding the specimens 
 [23] .
 Barriers to Implementing a Global Biospecimen 
Network 
 There are a growing number of biobanks around the 
world that actively promote collaboration with investiga-
tors; however, several challenges which inhibit clinical in-
vestigators from identifying and analysing the right co-
horts in the discovery and validation of molecular diag-
nostics and biomarkers remain. The biggest of these 
challenges include: (1) access to sufficient data to identify 
eligible patient cohorts for a study, (2) gaining broad in-
formed consent, (3) normalizing and merging results 
from biospecimens collected with different methods or 
under different circumstances, (4) clarifying custodial 
roles and access rights for banked biospecimens and the 
matched clinical data, (5) gaining permission to access 
samples from studies with limited biomaterials, and (6) 
establishing methods for addressing missing data and 
metadata  [24] .
 Finding the Right Biospecimens 
 Since there is no centralized resource describing avail-
able biobanked specimen collections, one of the largest 
challenges for biomarker developers is in finding avail-
able patient cohorts to develop and validate biomarkers 
for a specific clinical use. If investigators do not know a 
biobank resource that contains the required biospeci-
mens, the most common path biomarker developers fol-
low is to conduct a literature search to find investigators 
who have conducted studies and banked specimens that 
may address the required needs. The biomarker devel-
oper then contacts these investigators to understand 
whether these biospecimens are available for new bio-
marker research. The investigator then must confirm that 
a sufficient number of specimens with the necessary qual-
ity and the appropriate informed consent remain from 
the original study. Often the attrition rate for these sam-
ples is as high as 50% for each round of research analysis 
 [24] . The residual number of eligible samples is often in-
sufficient to support a new biomarker discovery study. In 
cases where enough appropriate biospecimens are identi-
fied, there is typically a long contracting period to gaining 
access as intellectual property rights, the budget, publica-
tion rights, and the future use of the data are negotiated.
 Lack of Standardized, Computationally Readable 
Data Formats and State-of-the-Art Informatics 
 Conclusions derived from biospecimens are only as 
good as the quality of the samples that are collected. How-
ever, this also applies to the data surrounding the sam-
ples. Biobank users have to be able to fully track samples 
in interoperable electronic systems that pay particular at-
tention to the quality and security of the data. There is an 
urgent need for stringently standardized data manage-
ment procedures, computationally readable formats, and 
commonly shared and accepted terminologies to repre-
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sent medical conditions. State-of-the-art, secure data 
storage as well as high-quality digital curation and anno-
tation of information related to the biosamples are often 
underappreciated but essential. Not paying attention to 
downstream interoperability and data integration dra-
matically diminishes the usefulness of the biosamples and 
associated data. We currently witness a change in bio-
banking from locally stored samples and annotation to 
international, virtual biobank networks. The informatics 
capability of providing user-friendly, controlled access to 
samples and data within a harmonized, overarching in-
formatics ecosystem will become one of the key criteria 
for a well-functioning biobank. There is a need to connect 
the exploding amount of data to highly automated work-
flows and data analysis pipelines that provide support for 
the integration of data from different sources. Artificial 
intelligence approaches are about to take centre stage in 
the next years. They all rely on state-of-the-art standards 
in clinical, genomic, and translational data. These need to 
be built in from the beginning in the operation of bio-
banks  [25] .
 Personal Data Protection and Specific Informed 
Consent Requirements 
 Establishing the right balance between protecting the 
privacy of patients and allowing optimal use of biospeci-
men samples is generally difficult to achieve. For exam-
ple, some ethics committees may prohibit the use of pa-
tient samples for the development of commercial prod-
ucts  [26] . While this restriction may appear to some to be 
reasonable, the goal of most biomarker discovery efforts 
is meant to lead to commercial tests that will benefit all 
patients, and therefore this requirement reduces the util-
ity of biospecimens for discoveries that could enhance pa-
tient care. Moreover, the refusal of some ethics commit-
tees to even ask patients whether or not they are willing 
to allow such use may be considered disrespectful of pa-
tients’ autonomy.
 Tissue Collection and Management 
 Some of the biggest challenges limiting biospecimens’ 
utility stem from their considerable heterogeneity. Some 
biospecimen samples are quite small, some oncology 
specimens have low fractions of tumour, and often oncol-
ogy tumour specimens lack a matched normal reference 
sample. Often standard pre-analytical procedures can 
markedly impact results or dictate what technologies can 
be applied to a specimen  [27] . Variations can be intro-
duced at many different steps during the collection, pres-
ervation, and storage of biospecimen samples. For in-
stance, formaldehyde fixation can cause the biochemical 
modification of RNA- and DNA-based biomarkers. Tis-
sue fixation time, temperature, and pH have a major im-
pact on chemical modifications and cross-links of DNA 
or RNA with proteins, which may complicate purifica-
tion and result in analysis artefacts  [28] . In addition to 
fixation-related effects, RNA profiles in tissues can be al-
tered during processing by gene induction, gene down-
regulation, and RNA modification and degradation  [29] . 
Standardizing and documenting the whole pre-analytical 
process of sample management – ranging from collection 
from the patient [e.g., type of collection device, treatment 
(medication/surgical procedure)], transport (time and 
temperature affecting responses to ischemia), processing 
(e.g., selection of appropriate parts of a tissue), stabiliza-
tion (fixation in formalin or freezing), and storage to iso-
lation of the various biomolecules – is increasingly recog-
nized as critical to performing reproducible, interpretable 
research. The European Committee for Standardization 
(CEN) has recently published technical specifications 
(‘Molecular in-vitro diagnostic examinations – specifica-
tions for pre-examination processes’) that refer to the ex-
isting ISO standard 15189. These technical specifications 
provide the basis for new ISO standards that are current-
ly under development. An attempt has been made with 
the Biospecimen Reporting for Improved Study Quality 
(BRISQ) initiative to enforce the inclusion of a descrip-
tion of the quality of samples used in publications  [30] . 
Under this guideline, reviewers are provided with a list of 
variables describing the samples used when evaluating 
publications involving human biomaterials. However, as 
new insights are gained into how research reproducibility 
can be affected by pre-analytical biospecimen processing, 
it is likely that these lists will need to be broadened to keep 
the literature current on all the artefacts that can affect the 
interpretation of data published in articles using biospec-
imens  [31] .
 Control of Samples and Clinical Databases 
 With each clinical biobank cohort, different rules and 
kinds of governance may apply as to who has control and 
the decision-making authority over both the samples and 
associated clinical data. In some cases, different parties 
with differing priorities may control the clinical data and 
the biospecimen samples. For example, a pharmaceutical 
company may sponsor a clinical trial demonstrating the 
utility of one drug over another where the biospecimens 
are collected and managed by a collaborating study group. 
In this example, the pharmaceutical company may not 
want to provide access to the clinical data if there is a risk 
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that further studies may show that only a small propor-
tion of patients benefit from their drug. If the study is not 
powered to address this question, the result could be a 
regulatory request for further, expensive clinical trials in 
defined subpopulations.
 Whenever possible, biospecimens should be made 
available to those researchers who can best maximize the 
utility of these samples, even if these researchers are in the 
private sector. Considering the custodianship of samples 
based on research priority should prevent samples from 
being imprisoned in silos  [32] .
 Finite Opportunities to Use Well-Characterized 
Biospecimens 
 One of the challenges facing those who manage high-
value biospecimen collections is deciding which investiga-
tors should have access to the resource. This decision is 
compounded in complexity by dramatic advances in assay 
technology that permit vast increases in information that 
can be gained from very limited numbers of specimens. 
Depending on the biomaterial collected, there may typi-
cally be only one or two opportunities to assay these sam-
ples in a comprehensive study; therefore, it is wise to be 
thoughtful when prioritizing research opportunities using 
these biospecimen resources for a biomedical discovery. 
Often supplies of certain types of tissue such as serum, 
plasma, and biopsies are limited; thus, long-term planning 
is necessary to decide how these resources are most effec-
tively used  [33] . It is generally established that developing 
a predictive marker for the clinic requires that develop-
ment cohorts be based on randomized trials followed by 
validation in completely separate clinical cohorts  [34] . 
This creates a dilemma, since typically only one or two 
prospective randomized clinical trials are conducted for a 
drug in development. Study designs that make optimal use 
of these samples should be produced using sound statisti-
cal methods. Creative approaches using cohort splitting or 
other strategies that minimize specimen numbers while 
maximizing the discovery potential have been devised,
although these may, paradoxically, create a suboptimal 
design for biomarker discovery if the number of markers 
needed to capture the predictive effect is large and when 
the biomarker effect sizes are small.
 Lack of Longitudinal Data and Sample Collection 
 As the oncology community gains experience using 
targeted agents and understanding of the course of dis-
ease in patients given these drugs, modes of refractory 
disease recurrence and drug resistance are emerging. As 
a result, longitudinal biospecimen collections are increas-
ingly needed for cancer and other chronic diseases. Stud-
ies should be designed to take serial biospecimen samples, 
typically at baseline, at intervals of treatment cycles, and 
finally at disease progression. These specimens are paired 
with longitudinal data, allowing investigators to assess 
the impact of clinical interventions over time and to in-
vestigate the mechanisms of disease progression. By test-
ing biospecimen samples collected before and after treat-
ment, insight can be gained into the initial impact of a 
therapy followed by emergent resistant disease forms. 
Historically, most clinical study designs collected bio-
specimens only at a single time point, which generally 
does not provide the full picture of a patient’s disease 
characteristics and disease course. One of the examples of 
such a longitudinal biorepository would be the EORTC 
SPECTA programme  [35] .
 Possible Solutions to Improve the Use of 
Biospecimens 
 There are many opportunities for collaboration to im-
prove access to quality-defined biospecimens and the as-
sociated clinical information needed for biomarker dis-
covery. Many of these are appearing as new initiatives 
prospectively collecting samples which will be needed for 
tomorrow’s discoveries. The rate of evolution of knowl-
edge of the best practices for collecting and storing bio-
specimens has become astonishing. At the same time, 
new technologies are becoming refined in performance. 
Molecular profiling can be done on single cells and on 
highly enriched populations of cells sorted by flow cy-
tometry. This trend tells us that even very small amounts 
of tissue could become rich sources of discovery, and that 
every effort should be made to obtain consent and pre-
serve all biospecimens from clinical trials, drug registries, 
and the like. Ultimately, this material is what enables the 
transformative discoveries that lead to new therapies. 
There are also many national and international initiatives 
which are working to address these challenges and facili-
tate the harmonization of biobanks, as outlined in  table 1 .
 Opportunities to Improve the Use of Biospecimens 
 Programmatic and logistic coordination of subject sam-
pling planning is beneficial when multiple studies address-
ing related scientific questions are being conducted, as this 
allows direct comparisons of the data and provides the 
ability to validate findings from one study in the next  [36] .
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 Table 1. Organizations and initiatives supporting the harmonization of biobanking infrastructures, standards, and research
Name of organization Scope Mission Website
Biobanking and 
Biomolecular 
Resources Research 
Infrastructure 
(BBMRI-ERIC)
Europe BBMRI-ERIC will increase efficacy and excellence of European bio-medical research 
by facilitating access to quality-defined human health/disease-relevant biological 
resources through:
– the inclusion of associated data in an efficient and ethically and legally compliant 
manner;
– by reducing the fragmentation of the bio-medical research landscape through 
harmonisation of procedures, implementation of common standards and fostering 
high-level collaboration; and
– by capacity-building in countries with less developed biobanking communities 
thereby contributing to Europe’s cohesion policy and strengthening the ERA
http://bbmri-eric.eu/
Biorepositories and 
Biospecimen Research 
Branch (BBRB)
USA The Biorepositories and Biospecimen Research Branch (BBRB) of the Cancer 
Diagnosis Program (CDP) provides leadership, tools, resources, and policies in 
biobanking for the global biomedical research community, to enable translational 
research and precision medicine for patients. BBRB develops biorepository standards 
and facilitates Biospecimen Science studies that form the basis of evidence-based 
practices to guide clinical cancer research and other biomedical studies which utilize 
biospecimens
http://biospecimens.
cancer.gov/default.asp
Canadian Tumour 
Repository Network
Canada Vision: to create new opportunities by providing leadership in biobanking to fuel 
translational cancer research that will improve cancer outcomes in Canada and 
worldwide
Mission: to enhance the capacity and quality of biobanking through standardization 
and improvement of biobanking processes and frameworks
http://www.ctrnet.ca/
CAP Biorepository 
Accreditation Program
USA Accreditation by the College of American Pathologists (CAP) focuses on quality, 
accuracy, and procedural consistency upon which patient outcomes directly depend. 
First in the industry to do so, the CAP will now accredit biorepositories, providing you 
the means to attain and maintain standardization and confidence that you are 
following best practices
http://www.cap.org/apps/
docs/laboratory_
accreditation/lap_info/
bio_brochure_042011.pdf
French standard NF 
S96-900: 2011 Quality 
of Biological Resources
France NF S96-900: a French national norm, which specifies the requirements for the 
management system of a Biological Resource Centre (BRC) and the quality of 
biological resources. Specific evaluation tools are used for this certification
http://www.
euroqualitysystem.com/
en/our-offers/nf-s96-900/
Human Tissue Authority 
(HTA)
UK The HTA is a regulator set up in 2005 following events in the 1990s that revealed a 
culture in hospitals of removing and retaining human organs and tissue without 
consent. This organization regulates organisations that remove, store and use human 
tissue for research, medical treatment, post-mortem examination, education and 
training, and display in public
http://www.HTA.gov.uk
International Society 
for Biological and 
Environmental 
Repositories (ISBER) 
Biospecimen Science 
Working Group
Inter-
national
ISBER is the only global forum that addresses harmonization of scientific, technical, 
legal, and ethical issues relevant to repositories of biological and environmental 
specimens
http://www.isber.org/
NCRI’s Confederation of 
Cancer Biobanks (CCB)
UK The NCRI’s Confederation of Cancer Biobanks (CCB) is a consortium of biobanks 
and biosample collections based in the UK, established to encourage greater 
coordination and promote harmonisation between biobanks – enabling them to share 
best practice and raise awareness of their collections with researchers. There are now 
over 30 member biobanks and the CCB assists biobank development by providing 
advice and mutual support
http://ccb.ncri.org.uk/
TuBaFrost (European 
Human Frozen Tumour 
Tissue Bank Network) 
and EurocanPlatform
Europe EurocanPlatform is a European FP7 project with the aim to set up a European 
Platform for Translational Cancer Research. Biobanking is one of the Work Packages 
in the project, where OECI-TuBaFrost was chosen as exchange platform and biobank/
sample tracker. Documents were assembled to be used for members in the 
EurocanPlatform consortium to harmonize and standardize their collections to be 
used in the platform. […] In the biobanking work package we use the experience of 
other European biobanking projects to build upon. Work on the future view and 
opportunities of biobanking. Identify roadblocks and alternative solutions, seeking the 
cooperation of organisations within EurocanPlatform, ECPC, OECI, ECCO and 
EORTC. [The main outcomes are published by Riegman et al. [20].]
http://www.tubafrost.org/
index.php
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 Proactive Tissue Collection 
 There is a common understanding among several 
groups around the world that there is a distinct need to 
collect well-characterized biospecimens to support dis-
ease treatment research. Many of these initiatives are fo-
cused on collecting samples which are intended to answer 
specific clinical questions or on collecting uniform tissue 
samples of a specific disease. One of the best examples of 
this type of programme is the NCI’s PLCO (Prostate, 
Lung, Colorectal, and Ovarian) Cancer Screening Trial. 
In this study, the participants were randomized into two 
arms: one arm where participants underwent periodic ex-
aminations for prostate, lung, colorectal, and ovarian 
cancer and a control arm receiving usual care from their 
health care provider. The participants in the intervention 
arm were asked to provide blood samples at specified 
time intervals. This approach provided a large repository 
of serial blood samples from initially healthy people. In 
addition, this group of researchers collected FFPE tissue 
from study participants who later developed one of the 
selected study cancers. Additional study specimens and 
data were collected on specific subsets of patients. This 
well-planned and -organized biospecimen repository 
now has approximately 2.9 million biologic specimens 
which are available for researchers. This resource has 
contributed to a large number of research projects, al-
though very few of the study requests for biospecimen 
access had the objective to develop or validate biomarkers 
for the early detection of prostate, lung, colorectal, or 
ovarian cancer. This initiative provides a successful case 
study, since ‘well-documented, standardized guidelines 
and procedures for each step in the complex workflows 
of biospecimen collection, processing, storage, requisi-
tion, and distribution, as well as data management, were 
essential for ensuring maximum use of this unique re-
source for a variety of research studies’  [26] .
 Another area of research which benefits from longitu-
dinal biospecimen collections is that concerned with var-
ious brain disorders, as such registries can track disease 
progression. One of the best examples is from the Euro-
pean Huntington’s Disease Network’s (EHDN), which is 
a multilingual, multinational prospective observational 
study of Huntington’s disease in Europe. This registry 
uses data collection (demographics, phenotype, geno-
type, medication, comorbidities, and biosamples) which 
follows a standard protocol across countries. As part of 
this study, there often are substudies which may focus on 
particular areas of interest such as a new drug  [37] . For 
example, LEGATO-HD is a phase II double-blind ran-
domized clinical research trial that will look into the safe-
ty of an investigational drug called laquinimod and will 
collect blood samples, offering the potential to develop a 
companion diagnostic  [38] . Besides the EHDN, there are 
studies working with banked samples that focus on defin-
ing biomarkers for other brain disorders; Biomarkers for 
Alzheimer’s and Parkinson’s Disease (BIOMARKAPD) 
is a European multicentre study funded by the EU Joint 
Programme-Neurodegenerative Disease Research which 
aims to define biomarkers for the diagnosis and progno-
sis of Alzheimer’s disease and Parkinson’s disease  [39] . By 
continuing to fund these types of initiatives, the number 
of opportunities to identify meaningful biomarkers and 
therapies to treat various brain disorders will increase.
 Evaluating Archived Population-Based Biospecimens 
with Next-Generation Sequencing 
 Preliminary studies have demonstrated the utility of 
archived FFPE samples as a source of DNA for genome-
wide sequencing studies, although the age of the samples 
was found to impact the coverage of the target region in 
the process used  [40] . More studies are needed to better 
understand the best way to apply new technologies to old-
er stored and preserved biospecimens of varying types. 
However, the initial results are promising, and recent his-
tory indicates a pace of innovation likely to overcome 
technical barriers to the full genomic and proteomic char-
acterization of most biospecimens, even those of very 
limited quantity.
 Conclusions and Recommendations 
 One of the key goals in supporting the development of 
value-based diagnostics is to ensure access to high-quali-
ty biospecimens that are harmonized across biobanks 
 [41–43] . This may best be achieved if the following 9 
items are dealt with:
 1  A simplified, streamlined, and coordinated EU legal 
framework to stimulate international secondary use of 
biospecimen research projects 
2  Better access to biosamples and data through empow-
erment of patients, standardized access procedures 
(e.g., material transfer agreements), and professional 
governance of biobanks 
3  Better standardization of biospecimen quality, with 
implementation of CEN and ISO standards becoming 
essential for biomarker development 
4  A platform that allows researchers to search and iden-
tify biospecimens that are well suited for use in research 
to develop and validate new value-based diagnostics 
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5  Biological samples need to be linked to detailed clinical 
information that includes basic, key data values that 
are standardized across biobanks and studies 
6  The biosamples collected within clinical trials and the 
scope of consent should allow the samples to be made 
available for research outside of the scope of clinical 
trials 
7  More emphasis on longitudinally collected samples 
and clinical data that are available for research 
8  Retrospective use of samples collected prior to the in-
troduction of specific consent, including for next-gen-
eration sequencing, should be allowed on the basis of 
Article 32 of the Declaration of Helsinki; specific rec-
ommendations should be developed on an interna-
tional level about how to deal with findings relevant to 
individual patients in this case 
9  Improved benefit for society by open access to re-
search data generated by the analysis of biospecimens 
 Pilot Projects 
 As the opportunities and challenges in organizing ap-
propriate biospecimen resources will continue to be-
come more complex, there is an ongoing need to support 
pilot projects that can be funded by organizations such 
as the Innovative Medicines Initiative (IMI) and Hori-
zon 2020 and prioritized by the upcoming International 
Consortium for Personalised Medicine (IC PerMed). 
The goal would be not to re-create systems but to sup-
port increased collaboration among the many valuable 
programmes that already exist. For example, one work 
group formed by the NCI proposed developing a pilot 
study to evaluate the feasibility of combining specimens 
from suitable studies to better understand the variability 
across studies  [41] . Groups like BBMRI-ERIC are well 
positioned to coordinate these types of pilot project 
across the many stakeholders involved in this field to
develop a more sustainable and harmonized system of 
biobanking.
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